Futibatinib

{
  "id": "MLC-T-ONC-003375",
  "term": "Futibatinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with intrahepatic cholangiocarcinoma (a type of cancer that forms in the bile ducts inside the liver) that has spread or cannot be removed by surgery and has an FGFR2 gene fusion or other change in the structure of the FGFR2 gene. It is used in patients whose cancer has already been treated. It is also being studied in the treatment of other types of cancer. Futibatinib blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Lytgobi.",
    "An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types."
  ],
  "synonyms": [
    "Lytgobi"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/futibatinib/"
}